Published in Arthritis Rheum on January 01, 1992
Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest (1992) 1.79
Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther (2014) 1.50
Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol (1997) 1.43
IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest (1996) 1.34
Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest (1999) 1.29
Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum (2009) 1.24
Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther (2007) 1.23
Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther (2009) 1.22
Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm (2014) 1.16
Molecular aspects of regulation of collagen gene expression in fibrosis. J Clin Immunol (2005) 1.13
Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem (2014) 1.12
Resistin-like molecule-beta in scleroderma-associated pulmonary hypertension. Am J Respir Cell Mol Biol (2009) 1.12
Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol (2010) 1.07
Increased levels of alternatively spliced interleukin 4 (IL-4delta2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin Diagn Lab Immunol (1999) 1.05
Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol (2011) 1.03
Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. Clin Exp Immunol (2002) 1.01
Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol (2001) 0.98
Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine (2011) 0.98
Pediatric scleroderma: systemic or localized forms. Pediatr Clin North Am (2012) 0.96
T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum (2008) 0.96
Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res (1995) 0.96
Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol (2006) 0.91
Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin Exp Immunol (1999) 0.91
Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther (2015) 0.90
mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Res Ther (2011) 0.87
CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol (2016) 0.86
Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol (2001) 0.86
Proteasome inhibition prevents development of experimental dermal fibrosis. Inflammation (2012) 0.83
Interleukin 4 in systemic sclerosis: not just an increase. Clin Diagn Lab Immunol (1999) 0.82
A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis. PLoS One (2015) 0.82
Interferon beta-1a-induced morphea. JAAD Case Rep (2014) 0.82
Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunology (2013) 0.81
Elevated serum L-selectin levels and decreased L-selectin expression on CD8(+) lymphocytes in systemic sclerosis. Clin Exp Immunol (2001) 0.80
The IL-33 gene is related to increased susceptibility to systemic sclerosis. Rheumatol Int (2016) 0.79
Expression of types I, III and IV collagen genes in fibrotic skin and nerve lesions of toxic oil syndrome patients. Clin Exp Immunol (1993) 0.77
The natural organosulfur compound dipropyltetrasulfide prevents HOCl-induced systemic sclerosis in the mouse. Arthritis Res Ther (2013) 0.77
Autoimmune mechanisms of scleroderma and a role of oxidative stress. Self Nonself (2011) 0.77
Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity. Springerplus (2016) 0.77
Expression of ectopeptidases in scleroderma. Ann Rheum Dis (1995) 0.77
Mucosa-associated lymphoid tissue lymphoma (MALT) of salivary glands and scleroderma: a case report. Clin Rheumatol (2004) 0.77
Increased circulating fibrinogen-like protein 2 in patients with systemic sclerosis. Clin Rheumatol (2012) 0.76
Mapping of the immunodominant T cell epitopes of the protein topoisomerase I. Ann Rheum Dis (2004) 0.76
Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts. Rheumatology (Oxford) (2010) 0.76
Deep morphea induced by interferon-β1b injection. JAAD Case Rep (2016) 0.75
Targeting STAT4 in systemic sclerosis: a promising new direction. Expert Rev Clin Immunol (2011) 0.75
Interleukin-6 in scleroderma: comment on the article by Needleman et al. Arthritis Rheum (1992) 0.75
Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys. Sci Rep (2016) 0.75
Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. Semin Arthritis Rheum (2015) 0.75
Targeted Therapy in Systemic Sclerosis. Rambam Maimonides Med J (2016) 0.75
Morphea and Eosinophilic Fasciitis: An Update. Am J Clin Dermatol (2017) 0.75
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum (2001) 3.15
Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med (2000) 3.01
New radiographic grading scales for osteoarthritis of the hand. Reliability for determining prevalence and progression. Arthritis Rheum (1989) 2.77
Body mass index in young men and the risk of subsequent knee and hip osteoarthritis. Am J Med (1999) 2.38
Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum (1999) 2.22
Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J (2009) 1.85
Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med (2000) 1.79
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2000) 1.62
Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies. Neurology (2004) 1.55
Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol (1991) 1.51
A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut (2006) 1.50
Foot and ankle problems in rheumatoid arthritis. Foot Ankle Int (1994) 1.49
A man with diabetes and a swollen leg. Lancet (1999) 1.41
Reliability of grading scales for individual radiographic features of osteoarthritis of the knee. The Baltimore longitudinal study of aging atlas of knee osteoarthritis. Invest Radiol (1993) 1.35
Incidence of lung cancer in systemic sclerosis. J Rheumatol (1985) 1.22
Combination antibiotic therapy in staphylococcal endocarditis. The use of methicillin sodium-gentamicin sulfate therapy. Arch Intern Med (1976) 1.21
African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest (1998) 1.14
The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum (2001) 1.14
Aerosol immunization of humans with inactivated parainfluenza type 2 vaccine. N Engl J Med (1970) 1.13
The longitudinal course of hand osteoarthritis in a male population. Arthritis Rheum (1990) 1.06
Lack of association between augmentation mammoplasty and systemic sclerosis (scleroderma). Arthritis Rheum (1996) 1.04
Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. Lupus (1995) 1.01
Depressive symptoms associated with scleroderma. Arthritis Rheum (1996) 0.99
Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med (1984) 0.97
Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy. J Rheumatol (1986) 0.96
Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis. Hum Immunol (1997) 0.95
A deceptive case of amyloid myopathy: clinical and magnetic resonance imaging features. Arthritis Rheum (2001) 0.94
Monitoring digoxin therapy. The use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity. Q J Med (1978) 0.94
High-dose cyclophosphamide without stem cell rescue in scleroderma. Ann Rheum Dis (2007) 0.93
Systemic sclerosis (scleroderma): clinical, genetic, and serologic subsets. J Rheumatol (1987) 0.93
Factors associated with osteoarthritis of the hand in males: data from the Baltimore Longitudinal Study of Aging. Am J Epidemiol (1991) 0.93
Characterization of human synovial mast cells. J Rheumatol (1988) 0.92
Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology (Oxford) (2008) 0.91
Posterior tibial tendon dysfunction in rheumatoid arthritis. Foot Ankle Int (1995) 0.89
Serial pulmonary function in systemic sclerosis. Am J Med (1982) 0.89
Preincubation of human synovial cells with IL-1 modulates prostaglandin E2 release in response to bradykinin. J Immunol (1989) 0.88
Expansion of selected V delta 1+ gamma delta T cells in systemic sclerosis patients. J Immunol (1994) 0.88
Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum (2000) 0.87
The role of the human synovial fibroblast in monosodium urate crystal-induced synovitis. J Rheumatol (1983) 0.87
Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma. Ann Rheum Dis (2006) 0.87
HLA-DR4 and pulmonary dysfunction in rheumatoid arthritis. Am J Med (1987) 0.87
Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med (1984) 0.86
Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol (2000) 0.84
Aerosol immunization of humans with tetanus toxoid. J Immunol (1969) 0.84
When is scleroderma really scleroderma? J Rheumatol (2001) 0.84
Lung transplantation and systemic sclerosis. Ann Transplant (2000) 0.83
Rectosigmoid motility and myoelectric activity in progressive systemic sclerosis. Gastroenterology (1989) 0.83
Raynaud's phenomenon in older adults: diagnostic considerations and management. Drugs Aging (1999) 0.83
Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis. J Rheumatol (1998) 0.83
Symptoms of Raynaud's phenomenon in an inner-city African-American community: prevalence and self-reported cardiovascular comorbidity. J Clin Epidemiol (1999) 0.81
Failure of vasoldilator infusion to alter pulmonary diffusing capacity in systemic sclerosis. Am J Med (1991) 0.81
Increased expression of intercellular adhesion molecule 1 on the fibroblasts of scleroderma patients. Arthritis Rheum (1990) 0.81
Unusual manifestation of tuberculosis: TE fistula. Am J Med (1976) 0.81
Digital pressure-flow relationships in subjects with Raynaud's phenomenon. Angiology (1985) 0.80
Abnormal exhaled ethane concentrations in scleroderma. Biomarkers (2006) 0.79
Osteoarthritis: practical management in older patients. Geriatrics (1984) 0.79
Three cases of osteonecrosis of the lunate bone of the wrist in scleroderma. Clin Exp Rheumatol (2000) 0.79
Characterization of the class I HLA 9.2-kb PVU II restriction fragment length polymorphism. Linkage to HLA-A and lack of disease association. Arthritis Rheum (1989) 0.78
Management of systemic sclerosis: the art and science. Semin Cutan Med Surg (1998) 0.78
Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma. Arthritis Rheum (2000) 0.78
Systemic and secretory antibody response of atopic and non-atopic individuals in intranasally administered tetanus toxoid. Clin Allergy (1973) 0.78
Absence of positional change in pulmonary diffusing capacity in systemic sclerosis. Am J Med (1983) 0.78
The "tank top sign": a unique pattern of skin fibrosis seen in pansclerotic morphea. Ann Rheum Dis (2009) 0.78
Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial. J Rheumatol (1987) 0.77
HLA-DQw alloantigens and pulmonary dysfunction in rheumatoid arthritis. Chest (1988) 0.77
Primary pulmonary hypertension is not associated with scleroderma-like changes in nailfold capillaries. Chest (2001) 0.77
Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon. J Rheumatol (1995) 0.76
Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. J Rheumatol (1994) 0.76
Effect of Mlsa on antigen presentation to class II-restricted T cells. J Immunol (1988) 0.75
Rheumatoid arthritis II: systemic manifestations. Md State Med J (1982) 0.75
Aseptic meningitis from over-the-counter ibuprofen. Lancet (1988) 0.75
Management of Severe Raynaud's Phenomenon. J Clin Rheumatol (1996) 0.75
Frequency of augmentation mammoplasty in patients with systemic sclerosis: data from the Johns Hopkins-University of Maryland Scleroderma Center. J Clin Epidemiol (1995) 0.75
Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. Am J Med (1985) 0.75
Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm. Arthritis Rheum (1987) 0.75
Increase in translaryngeal resistance during phonation in rheumatoid arthritis. Chest (1992) 0.75
Update on management of scleroderma. Bull Rheum Dis (2000) 0.75
Treatment of scleroderma. Curr Opin Rheumatol (1995) 0.75
Behavioral and pharmacologic interventions: the Raynaud's Treatment Study. Control Clin Trials (1999) 0.75